novartis_microsoft_ai_still006_4k

Novartis

3 October 2019Big PharmaRory O'Neill

Novartis and Microsoft to collaborate on AI in medicine

Novartis has teamed with Microsoft to launch a new artificial intelligence (AI) innovation lab, which it says has the potential to “transform” and “reimagine” medicine.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool